University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

BlueSphere Bio, Inc.

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

Therapeutics

Therapeutic Areas

ImmunologyRespiratoryOncology

Therapeutic Indications

Leukemia

Funding Stage

Series A+

Founders

Mark ShlomchikWarren ShlomchikConstantinos PanousisAlex Rowe

Website

https://bluespherebio.com/
BlueSphere Bio, Inc.

BlueSphere Bio is advancing cell therapies that direct the immune system toward cancer and other serious diseases. Built on University of Pittsburgh research and launched with UPMC Enterprises, the company uses its TCXpress platform to discover and characterize T-cell receptors for targeted treatments. [1]

Its lead investigational therapy, BSB-1001, is enrolling in a Phase 1 study for patients with high-risk blood cancers undergoing donor stem-cell transplantation. BlueSphere’s broader pipeline includes therapies targeting NPM1-mutated acute myeloid leukemia and recurrent respiratory papillomatosis, extending its approach to additional patient populations. [2]

Discover More with AI